Private Equity-Venture Capital (PE-VC) investments experienced a year-on-year decline of 32% in terms of value in April 2026, totaling $1.9 billion compared to $2.8 billion in April 2025, according to data from research firm Venture Intelligence.
The number of deals also dropped significantly, falling by 30% from 124 transactions in April 2025 to 87 in April 2026. Sequentially, the deal value nearly halved from $4.7 billion across 120 deals in March 2026.
For the first four months of 2026, total PE-VC investments reached approximately $12 billion across 435 deals, compared to $14.6 billion across 467 deals during the same period in the previous year.
Mega deals, defined as transactions over $100 million, also saw a decrease; only $1.1 billion was invested in six such deals in April 2026, down from $1.9 billion across seven deals in April 2025.
The largest transaction for the month was a $280 million investment raised by digital lending firm Kreditbee from a consortium including Motilal Oswal Alternates, Advent International, and PremjiInvest. Other significant deals included Apothecon Pharmaceuticals, which secured $270 million from Everstone, and hospital chain Baby Memorial Hospital, which raised $186 million from KKR.
Investments in early-stage companies fell to $253 million across 40 deals, while growth-stage investments remained stable at $520 million across 26 deals. However, late-stage investments sharply declined to $376 million, down from $653 million.
Notably, the average deal size in early-stage investments increased to $6 million, up from $3 million in April 2025. For growth-stage investments, the average deal size rose to $20 million from $12 million, while late-stage investments saw a decrease to $25 million from $33 million.
The data highlights ongoing challenges within the PE-VC sector, reiterating trends of declining investment values and deal counts.
Published on May 1, 2026.
